



NEW MEXICO
RETIREE
HEALTH CARE
AUTHORITY

Interagency Pharmaceuticals Purchasing Council

IPPC Member Updates
October 3, 2019

Tom Sullivan, President
Joe Montañó, Vice President
Doug Crandall, Secretary
David Archuleta, Executive Director

Background Information

Retiree Health Care Authority Act

- Created in 1990
- Created to provide comprehensive core group health insurance for persons who have retired from certain public service in New Mexico.
- Governed by 11-member Board of Directors
- Broad authority for administration of the Health Care Benefits Administration Program
 - Eligibility guidelines and requirements
 - Subsidy levels
 - Plan design
- Public employer groups - 302
 - All school districts and charter schools – 50%
 - All state agencies – 25%
 - Municipalities, counties & universities – 25%
- Active Members on Medical Plan – 55,087 (10/1/19)
 - Pre-Medicare – 15,389
 - Medicare – 39,698
 - Medicare Supplement – 23,107
 - Medicare Advantage – 16,591

Pharmacy Benefits

NMRHCA MEDICARE PLAN COMPARISON

Effective: January 1, 2020

BCBSNM MEDICARE SUPPLEMENT	BCBS Medicare Advantage Plan I	Presbyterian Medicare Advantage Plan I	UnitedHealthcare Medicare Advantage Plan I	Humana Medicare Advantage Plan I	BCBS Medicare Advantage Plan II	Presbyterian Medicare Advantage Plan II	UnitedHealthcare Medicare Advantage Plan II	Humana Medicare Advantage Plan II
----------------------------------	-----------------------------------	--	--	--	------------------------------------	---	---	---

Retail Pharmacy - 31-day

						\$310 Deductible			
Preferred Generic	\$5 - \$15	\$0 - \$5	\$0	\$15	\$4	\$0 - \$5	\$0	\$10	\$4
Non-Preferred Generic		\$5 - \$10	\$10	\$70	\$4	\$7 - \$12	\$10	\$35	\$4
Preferred Brand	\$30 - \$60	\$40 - \$45	\$45	\$35	\$40	\$40 - \$45	\$45	\$20	\$40
Non-Preferred Brand		\$90 - \$95	\$95	\$70	\$90	\$90 - \$95	\$95	\$35	\$90
Specialty Drug		33%	\$100	\$70	33%	25%	27%	\$35	33%
Non-Formulary	\$50 - \$125								

Mail Order - 90 day

Preferred Generic	*** Smart 90								
Preferred Generic	\$12 - \$35	\$15	\$0	\$30	\$0	\$15	\$0	\$20	\$0
Non-Preferred Generic		\$30	\$30	\$140	\$0	\$36	\$30	\$70	\$0
Preferred Brand	\$60 - \$120	\$135	\$135	\$70	\$80	\$135	\$135	\$40	\$80
Non-Preferred Brand		\$285	\$285	\$140	\$180	\$285	\$285	\$70	\$180
Non - Formulary	\$100 - \$250								

Prescription Coverage

Coverage Gap	No	No	No	No	No	No	Yes**	Yes**	Yes**
--------------	----	----	----	----	----	----	-------	-------	-------

NON-MEDICARE PRESCRIPTION DRUG PLAN ADMINISTERED BY EXPRESS SCRIPTS

<i>Copay (Retail)</i>	<i>Minimum</i>	<i>Maximum</i>
Generic	\$5	\$15
Preferred Brand	\$30	\$60
Non-Preferred Brand	\$50	\$125

Maximum of 34-day supply or 100 unit or as prescribed by your physician or an approved exception.

<i>Copay (Mail Order or **Smart 90)</i>	<i>Minimum</i>	<i>Maximum</i>	**90 day refill supply can be filled through Mail Order or through a retail pharmacy in the Smart 90 network. Visit www.express-scripts.com or call Express Scripts at 1-800-501-0987 for locations.
Generic	\$12	\$35	
Preferred Brand	\$60	\$120	
Non-Preferred Brand	\$100	\$250	

Maximum of 90-day supply or 300 units or as prescribed by your physician or an approved exception.

<i>Accredo (Special Pharmaceuticals)</i>	<i>Closed Network</i>
--	-----------------------

Performance Metrics

	RHCA EGWP & Commercial Combined	Government Retirement Plans - Combined	RHCA Pre-Medicare	Government Retirement Plans - Non-Medicare	RHCA Medicare (EGWP)	Government Retirement Plans - Medicare
Description	7-18 - 6-19	7-18 - 6-19	7-18 - 6-19	7-18 - 6-19	7-18 - 6-19	7-18 - 6-19
Average Member Age	67.0	72.1	54.5	56.4	75.5	75.9
Plan Cost Net PMPM	\$188.21	\$213.02	\$113.83	\$162.92	\$239.23	\$225.28
Plan Cost Net/Day	\$1.97	\$1.86	\$1.91	\$2.35	\$1.99	\$1.79
Plan Cost Net per Adjusted Rx	\$54.83	\$51.85	\$51.99	\$64.62	\$55.82	\$50.10
Nbr Adjusted Rxs PMPM	3.43	4.11	2.19	2.52	4.29	4.50
Generic Fill Rate	88.4%	90.6%	87.6%	88.8%	88.7%	90.9%
90 Day Utilization	60.1%	71.9%	48.6%	56.4%	64.0%	74.0%
Retail - Maintenance 90 Utilization	20.8%	24.9%	13.4%	4.6%	23.4%	27.7%
Home Delivery Utilization	39.3%	47.0%	35.2%	51.7%	40.7%	46.3%
Member Cost Net %	13.6%	14.2%	16.1%	13.9%	12.7%	14.3%
Specialty Percent of Plan Cost Net	49.7%	42.3%	48.0%	47.7%	50.3%	41.4%
Specialty Plan Cost Net PMPM	\$93.61	\$90.16	\$54.66	\$77.69	\$120.33	\$93.22
Formulary Compliance Rate	98.5%	98.8%	99.0%	98.6%	98.3%	98.8%

- Plan costs net PMPM decreased \$1.59 (-0.8%) to \$188.21, primarily driven by the Unit Cost Trend Component
- Specialty plan cost net PMPM increased \$8.99 (+10.6%) to \$93.61, primarily driven by the Specialty Utilization Trend Component
- Generic fill rate decreased 0.2 percentage points to 88.4%

Top 25 Drugs

Top Drugs by Plan Cost Net

Top Drugs by Plan Cost Net													
7-18 - 6-19													
7-17 - 6-18													
% Change													
AUM Strategy	Rank	Peer Rank	Brand Name	Indication	Adj. Rxs	Pts.	Plan Cost Net	Plan Cost Net PMPM	Rank	Adj. Rxs	Pts.	Plan Cost Net PMPM	Plan Cost Net PMPM
PA	1	2	REVLIMID*	CANCER	333	43	\$4,789,589	\$10.30	2	268	37	\$7.15	44.1%
PA/DQM	2	7	IMBRUVICA*	CANCER	252	32	\$2,696,303	\$5.80	3	190	24	\$4.10	41.4%
ST/PA/DQM	3	1	HUMIRA PEN*	INFLAMMATORY CONDITIONS	676	80	\$2,538,709	\$5.46	1	970	111	\$8.25	-33.8%
PA	4	3	ELIQUIS	ANTICOAGULANT	7,856	1,004	\$1,833,065	\$3.94	9	5,360	700	\$2.63	49.9%
PA	5	9	XARELTO	ANTICOAGULANT	6,418	833	\$1,441,964	\$3.10	8	5,483	769	\$2.75	12.6%
ST/PA/DQM	6	24	XTANDI*	CANCER	148	20	\$1,385,887	\$2.98	5	154	22	\$3.19	-6.6%
ST/PA/DQM	7	5	ENBREL SURECLICK*	INFLAMMATORY CONDITIONS	408	46	\$1,374,597	\$2.96	4	467	53	\$3.46	-14.5%
ST	8	8	LYRICA	PAIN/INFLAMMATION	3,421	503	\$1,254,814	\$2.70	7	3,408	496	\$3.03	-10.8%
PA/DQM	9	4	TRULICITY	DIABETES	3,184	395	\$1,180,958	\$2.54	14	2,268	290	\$1.97	28.8%
PA/DQM	10	12	IBRANCE*	CANCER	106	17	\$1,112,055	\$2.39	6	143	18	\$3.14	-23.8%
PA/DQM	11	20	IMATINIB MESYLATE*	CANCER	112	11	\$1,085,485	\$2.33	11	117	11	\$2.28	2.4%
ST	12	29	AUBAGIO*	MULTIPLE SCLEROSIS	185	18	\$1,014,201	\$2.18	12	178	17	\$2.06	6.0%
DQM	13	38	XIFAXAN	GI DISORDERS	587	124	\$987,129	\$2.12	15	521	110	\$1.75	21.6%
ST/DQM	14	13	JANUVIA	DIABETES	7,055	819	\$972,254	\$2.09	13	6,781	809	\$2.03	3.1%
ST/PA/DQM	15	49	FORTEO*	OSTEOPOROSIS	336	48	\$939,707	\$2.02	10	398	61	\$2.44	-17.3%
PA	16	54	AFINITOR*	CANCER	54	8	\$777,615	\$1.67	20	42	6	\$1.32	26.4%
ST/PA/DQM	17	27	ZYTIGA*	CANCER	75	15	\$769,203	\$1.65	38	45	13	\$0.96	72.6%
N/A	18	40	SHINGRIX	VACCINATIONS	4,601	3,198	\$719,947	\$1.55	85	1,558	1,275	\$0.51	206.5%
ST/PA	19	88	OPSUMIT*	PULMONARY HYPERTENSION	85	11	\$695,449	\$1.50	46	50	7	\$0.87	71.9%
PA/DQM	20	41	OFEV*	IDIOPATHIC PULMONARY FIBROSIS	73	8	\$693,636	\$1.49	36	50	6	\$0.97	53.5%
ST/PA	21	10	HUMIRA(CF) PEN*	INFLAMMATORY CONDITIONS	180	36	\$650,315	\$1.40	835	2	1	\$0.02	8979.6%
ST/PA/DQM	22	21	VICTOZA 3-PAK	DIABETES	1,210	162	\$633,022	\$1.36	23	1,197	161	\$1.27	6.8%
PA	23	25	POMALYST*	CANCER	37	8	\$630,356	\$1.36	32	35	6	\$1.06	28.4%
N/A	24	130	LEVOTHYROXINE SODIUM	THYROID DISORDERS	92,635	8,863	\$628,537	\$1.35	19	91,902	8,936	\$1.40	-3.7%
PA/DQM	25	46	TAGRISSO*	CANCER	35	5	\$622,440	\$1.34	117	8	3	\$0.36	271.4%
				Total Top 25:	130,062		\$31,427,239	\$67.59		121,595		\$58.97	14.6%
				Differences Between Periods:	8,467		\$3,491,175	\$8.62					

Cost Containment

Trend Management	Plan Cost Savings	Plan Cost Savings PMPM	Program Description
Prior Authorization	\$5,262,657	\$11.32	A review of the indication and other pertinent information is performed to confirm that products are covered only when clinical criteria are met.
Drug Quantity Management	\$2,451,369	\$5.27	Review claims and allow FDA approved quantities
Step Therapy	\$1,173,660	\$2.52	Promote lower cost first line agents before more expensive brand name products.

Total Plan Cost Savings \$8,887,686 or \$19.11 PMPM

Reporting Period: 07/01/2018 - 6/30/2019

Cost Containment Continued

- Savon Program (4/1/19 – 9/26/19)
 - Net Savings - \$796,849 (185 participants)
 - Inflammatory Conditions - \$589,181
 - Humira, Enbrel, Xeljanz, Otezla, plus 10 others
 - MS - \$82,691
 - Aubagio, Gilenya, Copaxone, Avonex , Tecfidera
 - Oncology - \$80,670
 - Ibrance, Xtandi, Bosulif, Lunparza, plus 6 others
 - Hepatitis C - \$19,399
 - Epclusa and Harvoni
 - Hemophilia - \$8,175
 - Promacta and Granix
 - PAH - \$7,024
 - Asthma - \$5,419
 - Gastrointestinal - \$2,738
 - Osteoporosis - \$1,613
- Market Check Agreement
 - 18 months from 7/1/18